Search

Your search keyword '"Kriege, Oliver"' showing total 2 results
Start Over Author "Kriege, Oliver" Search Limiters Peer Reviewed Topic azacitidine
2 results on '"Kriege, Oliver"'

1. Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Author

Schuler, Esther, Wagner-Drouet, Eva-Maria, Ajib, Salem, Bug, Gesine, Crysandt, Martina, Dressler, Sabine, Hausmann, Andreas, Heidenreich, Daniela, Hirschbühl, Klaus, Hoepting, Matthias, Jost, Edgar, Kaivers, Jennifer, Klein, Stefan, Koldehoff, Michael, Kordelas, Lambros, Kriege, Oliver, Müller, Lutz P., Rautenberg, Christina, Schaffrath, Judith, Schmid, Christoph, Wolff, Daniel, Haas, Rainer, Bornhäuser, Martin, Schroeder, Thomas, and Kobbe, Guido

Subjects
Salvage Therapy, Sulfonamides, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Correction, Kaplan-Meier Estimate, DNA Methylation, Allografts, Bridged Bicyclo Compounds, Heterocyclic, Decitabine, Combined Modality Therapy, Thrombocytopenia, Leukemia, Myeloid, Acute, Leukocyte Count, Recurrence, Germany, Myelodysplastic Syndromes, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Drug Evaluation, Humans, Tumor Lysis Syndrome, Immunosuppressive Agents, Febrile Neutropenia, Retrospective Studies
Abstract

Treatment of relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a great challenge. Aiming to evaluate the combination of venetoclax and hypomethylating agents (HMAClax) for the treatment of relapse of myeloid malignancies after alloHSCT, we retrospectively collected data from 32 patients treated at 11 German centers. Venetoclax was applied with azacitidine (n = 13) or decitabine (n = 19); 11 patients received DLI in addition. HMAClax was the first salvage therapy in 8 patients. The median number of cycles per patient was 2 (1-19). All but 1 patient had grade 3/4 neutropenia. Hospital admission for grade 3/4 infections was necessary in 23 patients (72%); 5 of these were fatal. In 30 evaluable patients, overall response rate (ORR) was 47% (14/30, 3 CR MRD

Published
2021

2. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents : A retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Author

Schuler, Esther, Wagner-Drouet, Eva-Maria, Jost, Edgar, Kaivers, Jennifer, Klein, Stefan, Koldehoff, Michael, Kordelas, Lambros, Kriege, Oliver, Müller, Lutz P., Rautenberg, Christina, Schaffrath, Judith, Schmid, Christoph, Ajib, Salem, Wolff, Daniel, Haas, Rainer, Bornhäuser, Martin, Schroeder, Thomas, Kobbe, Guido, German Cooperative Transplant Study Group, Bug, Gesine, Crysandt, Martina, Dressler, Sabine, Hausmann, Andreas, Heidenreich, Daniela, Hirschbühl, Klaus, and Hoepting, Matthias

Subjects
Oncology, medicine.medical_specialty, Myeloid, medicine.medical_treatment, Azacitidine, Medizin, Decitabine, Salvage therapy, Hypomethylating agents, Hematopoietic stem cell transplantation, Neutropenia, Venetoclax, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Medicine, ddc:610, Relapse, Hematology, business.industry, General Medicine, medicine.disease, medicine.anatomical_structure, chemistry, 030220 oncology & carcinogenesis, Allogeneic hematopoietic stem cell transplantation, Original Article, DLI, business, 030215 immunology, medicine.drug
Abstract

Annals of hematology 100(4), 959-968 (2021). doi:10.1007/s00277-020-04321-x, Published by Springer, Berlin ; Heidelberg ; New York

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results